Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Obeticholic Acid Tablets, 5 mg and 10 mg, to market a generic equivalent of Ocaliva® Tablets, 5 mg and 10 mg, of Intercept Pharmaceuticals, Inc.
Obeticholic Acid Tablets (RLD Ocaliva) had estimated annual sales of USD 255 million in the U.S. (IQVIA MAT December 2022).
Lupin shares
The shares of Lupin on Thursday closed at Rs 648.80, down by 1.53 per cent.
Battle Of Sexes: Nick Kyrgios Wins At A Canter, Beats World No.1 Aryna Sabalenka 6-3, 6-3 In Controversial Tennis Match
Bombay High Court Acquits Teacher Sentenced Under POCSO, Cites Delay In FIR And Lack Of Credible Evidence
Donald Trump Meets Volodymyr Zelenskyy In Florida After Vladimir Putin Call, Signals Push For Ukraine Peace Deal
AAP Steps Up Mumbai Civic Poll Push, Releases Third Candidate List As Party Commits To Contest All 227 BMC Seats Without Alliance
